ANI Pharmaceuticals Inc (NAS:ANIP)

$ 56.86 -0.01 (-0.02%) Market Cap: 1.20 Bil Enterprise Value: 1.69 Bil PE Ratio: 0 PB Ratio: 2.95 GF Score: 85/100

Q3 2024 ANI Pharmaceuticals Inc Earnings Call Transcript
Nov 08, 2024

$61.44 (+5.24%)

Earnings
Q2 2024 ANI Pharmaceuticals Inc Earnings Call Transcript
Aug 06, 2024

$63.29 (+6.98%)

Earnings
Q1 2024 ANI Pharmaceuticals Inc Earnings Call Transcript
May 10, 2024

$68.05 (+3.29%)

Earnings
Q4 2023 ANI Pharmaceuticals Inc Earnings Call Transcript
Feb 29, 2024

$67.67 (+12.26%)

Earnings
ANI Pharmaceuticals Inc at Guggenheim Healthcare Talks Transcript
Feb 08, 2024
Q3 2023 ANI Pharmaceuticals Inc Earnings Call Transcript
Nov 08, 2023

$54.32 (-14.64%)

Earnings
Q2 2023 ANI Pharmaceuticals Inc Earnings Call Transcript
Aug 09, 2023

$61.08 (+9.21%)

Earnings
Q1 2023 ANI Pharmaceuticals Inc Earnings Call Transcript
May 08, 2023

$42.58 (+8.79%)

Earnings
ANI Pharmaceuticals Inc at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023
Q4 2022 ANI Pharmaceuticals Inc Earnings Call Transcript
Mar 09, 2023

$43.17 (+0.09%)

Earnings
Q3 2022 ANI Pharmaceuticals Inc Earnings Call Transcript
Nov 09, 2022

$34.74 (-9.20%)

Earnings
Q2 2022 ANI Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2022

$34.87 (+0.72%)

Earnings
Q1 2022 ANI Pharmaceuticals Inc Earnings Call Transcript
May 10, 2022

$25.28 (-3.24%)

Earnings
Q4 2021 ANI Pharmaceuticals Inc Earnings Call Transcript
Mar 15, 2022

$29.01 (-18.65%)

Earnings
Q3 2021 ANI Pharmaceuticals Inc Earnings Call Transcript
Nov 01, 2021

$55.89 (+49.52%)

Earnings
Q2 2021 ANI Pharmaceuticals Inc Earnings Call Transcript
Aug 06, 2021

$33.06 (-0.84%)

Earnings
ANI Pharmaceuticals Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 22, 2021
ANI Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 02, 2021
Q1 2021 ANI Pharmaceuticals Inc Earnings Call Transcript
May 07, 2021

$38.6 (+10.29%)

Earnings
Q4 2020 ANI Pharmaceuticals Inc Earnings Call Transcript
Mar 09, 2021

$29.96 (-1.25%)

Earnings
Q3 2020 ANI Pharmaceuticals Inc Earnings Call Transcript
Nov 05, 2020

$26.66 (-5.36%)

Earnings
Q2 2020 ANI Pharmaceuticals Inc Earnings Call Transcript
Aug 06, 2020

$29.5 (-4.84%)

Earnings
ANI Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 05, 2020
Q1 2020 ANI Pharmaceuticals Inc Earnings Call Transcript
May 07, 2020

$34.06 (-7.85%)

Earnings
Q4 2019 ANI Pharmaceuticals Inc Earnings Call Transcript
Feb 27, 2020

$48.25 (-18.68%)

Earnings
Q3 2019 ANI Pharmaceuticals Inc Earnings Call Transcript
Nov 06, 2019

$60.17 (-23.75%)

Earnings
Q2 2019 ANI Pharmaceuticals Inc Earnings Call Transcript
Aug 07, 2019

$72.62 (-12.04%)

Earnings
Q1 2019 ANI Pharmaceuticals Inc Earnings Call Transcript
May 09, 2019

$73.17 (+3.06%)

Earnings
Q4 2018 ANI Pharmaceuticals Inc Earnings Call Transcript
Feb 27, 2019

$64.71 (+5.91%)

Earnings

Q3 2019 ANI Pharmaceuticals Inc Earnings Call Transcript

Nov 06, 2019 / 03:30PM GMT

Release Date Price: $60.17 (-23.75%)

Transcript 8-K10-Q

Operator

Good morning, everyone, and welcome to the ANI's Third Quarter 2019 Earnings Call. (Operator Instructions). Please note, this call may be recorded. It is now my pleasure to turn this call over to today's program -- Mr. Arthur Przybyl. Please go ahead.

Arthur S. Przybyl

ANI Pharmaceuticals, Inc. - President, CEO & Director

Good morning, everyone. Welcome to ANI's earnings conference call for the third quarter 2019. My name is Art Przybyl, I am the CEO. And joining me today is Stephen Carey, our Chief Financial Officer.

Before we begin, I want to refer everyone to the forward-looking statements language in this morning's press release and ask each of you to review it carefully as important context for this conference call.

Discussions will also include certain financial measures that were not prepared in accordance with generally accepted accounting principles. Reconciliation of those non-GAAP financial measures can be found in our earnings release dated today.

ANI reported third quarter 2019 revenues of $51.3 million and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.